Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO) in a report released on Sunday. The firm set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Price Performance

Shares of CO stock opened at $0.80 on Friday. The stock has a market cap of $97.24 million, a P/E ratio of 1.25 and a beta of 0.16. Global Cord Blood has a fifty-two week low of $2.03 and a fifty-two week high of $5.50. The business has a fifty day simple moving average of $0.95 and a 200-day simple moving average of $1.22.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.